ClinicalTrials.gg
RecruitingNCT06445686REACTUpdated Aug 15, 2024

Ongoing Monitoring of Vital Signs in Patients With Idiopathic Pulmonary Fibrosis Before and After Acute Exacerbation.

An observational study in Idiopathic Pulmonary Fibrosis, sponsored by Biosency. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-15.

Sponsored by Biosency · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Idiopathic Pulmonary Fibrosis with a site in France — 10 open to participants now, 15 under way, 5 of them phase 3. Idiopathic Pulmonary Fibrosis · France.

Planned enrollment
12th of 13
30 · median 141
Started
2024
with 6 others
Observational
13 of 70
2 open now
Primary completion
2026-02
later than 2 of 14 live
Registered
62nd of 70
by date

Among the 70 studies in Idiopathic Pulmonary Fibrosis with a site in France, this one is the 12th largest by planned enrollment of the 13 observational ones that give a count, is one of 7 that started in 2024, is one of 13 observational ones, reaches primary completion later than 2 of the 14 other live ones, and was the 62nd registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

10 of the 70 studies in Idiopathic Pulmonary Fibrosis with a site in France are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 84 Idiopathic Pulmonary Fibrosis studies recruiting now, 55 (65%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Idiopathic Pulmonary Fibrosis with a site in France, or all of them as a file.
02

Study summary

The aim of this study is to assess the feasibility of early detection of acute exacerbations of idiopathic pulmonary fibrosis by the remote monitoring of vital signs.

The main question the study aims to answer is: Could a remote monitoring device allow for earlier detection of exacerbations with individualized monitoring and continuous data collection? All patients will receive conventional clinical follow-up based on their health status and clinical recommendations. At the same time, they will benefit from the Bora Care® medical remote monitoring device.

Read the detailed description

All patients will receive conventional clinical follow-up based on their health status and clinical recommendations. At the same time, they will benefit from the Bora Care® medical remote monitoring device.

To do this, they will be equipped with a Bora Band® connected wristband that measures vital signs at home, and the Bora Box® Gateway that ensures connectivity and allows automatic data uploading in real time to the Bora Connect® data visualization platform.

The home healthcare provider Air de Bretagne will be involved in the study to support each patient in the use of the connected wristband.

At the end of the follow-up period, the collected data will be retrospectively analysed to identify the most relevant metrics within the time series of vital signs for early detection of Idiopathic Pulmonary Fibrosis exacerbations, and to assess the feasibility of early detection of Idiopathic Pulmonary Fibrosis exacerbations using a score that could trigger an alert prior to the date the patient reports clinical signs or the date the pulmonologist is consulted for exacerbation of Idiopathic Pulmonary Fibrosis.

Procedure:

  • Inclusion Visit : 6-minute walk test and prescription of oxygen therapy
  • Home Installation Visit: installation of oxygen therapy by Air de Bretagne and setup of the Bora Connect® bracelet and Bora Box® Gateway
  • Follow-up Visit with the Pulmonologist at 6 months (M6): routine examinations, satisfaction questionnaire, and quality of life questionnaire
  • End of Study Visit with the Pulmonologist at 12 months (M12): routine examinations, satisfaction questionnaire, and quality of life questionnaire.

(In case of exacerbation, the follow-up will be extended by 3 months to collect post-exacerbation data.)

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis

Keywords

  • Idiopathic pulmonary fibrosis
  • Remote monitoring
  • Exacerbation
  • Prevention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with Idiopathic Pulmonary Fibrosis with indication for ambulatory oxygen therapy (Sp02 (peripheral oxygen saturation) ≤ 88% in ambient air during 6-minute walk test)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient over 18 years of age, ideally 50% male and 50% female
  • Patient with IPF with a known level of respiratory function (EFR and blood gas less than 3 months)
  • Stable patient, i.e. without hospitalisation or exacerbation in the last 3 months
  • Patient desaturating at 6MW in ambient air (AA) and requiring ambulatory oxygen therapy (SpO2 AA ⩽ 88%)
  • Patient not receiving walking or permanent oxygen therapy at baseline
  • Informed patient who has signed consent
  • Patient affiliated to a social security scheme
  • Patient not monitored by a home healthcare provider other than Air de Bretagne.

Exclusion criteria

Exclusion Criteria:

  • Vulnerable patient
  • Patient receiving ambulatory or permanent oxygen therapy at baseline
  • Patient already seen with another healthcare provider (e.g. OSAS)
  • Patient unable to use the Bora Band® tool and without access to a caregiver
  • Presence of co-morbidity considered unstable or very severe by the investigator
  • Patient protected, under guardianship or incapable of giving free and
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
30 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Assess the feasibility of early detection of acute IPF exacerbations with the Bora Care® Vital Signs Remote Monitoring Solution.

    Correlation between changes in time series of vital signs (heart rate, respiratory rate) in patients in the days prior to diagnosis of exacerbation of Idiopathic Pulmonary Fibrosis and onset of exacerbation of Idiopathic Pulmonary Fibrosis.

    Time frame: 1 year

Secondary outcomes

  1. Identify relevant metrics in the signals collected by the Bora Care® solution for early detection of medical events.

    Evolution of vital signs in patients on days prior to the date of other medical events during follow-up.

    Time frame: 1 year

  2. Assess compliance with the use of the Bora Care® bracelet by patients.

    Number of hours of wearing the Bora Band® bracelet normalised by the total number of hours of the remote monitoring session, information collected via the Bora Care® too.

    Time frame: 1 year

  3. Assess patient satisfaction and reassurance provided by the remote monitoring solution

    Subjective assessment by the patient of the device of the reassurance provided by the device, of the help to resume physical activity provided by the device, obtained using satisfaction questionnaires at M6 and M12. SF36 Quality of Life Questionnaire score collected at D0, M6 and M12.

    Time frame: 1 year

  4. Assess the satisfaction and adherence of healthcare professionals to the remote monitoring solution.

    Subjective assessment of health care professionals' satisfaction with and adherence to the Bora Care® remote monitoring solution, including an organizational impact assessment and an assessment of clinical relevance using a questionnaire at the end of the study.

    Time frame: 1 year

  5. Assess side effects related to the Bora Care® device.

    Number and nature of Bora Care® adverse events

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Chru Pontchaillou
    Rennes, 35000, France
    Recruiting
    • Stéphane Jouneau, MD · Contact0299282478
08

References and documents

Individual participant data

Plan to share: No — Not applicable. Data are not intended to be shared with other researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Feb 2026, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2024
First posted
Jun 6, 2024
StartActual
Jun 17, 2024
Primary completionEst.
Feb 2026
CompletionEst.
Feb 2026
Last update
Aug 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06445686
Lead sponsor
Biosency
Collaborators
Rennes University Hospital, Air de Bretagne, Association Fibroses Pulmonaires France
Responsible party
Sponsor
First posted
Jun 6, 2024
Start date
Jun 17, 2024
Primary completion
Feb 2026 (estimated)
Completion
Feb 2026 (estimated)
Last update
Aug 15, 2024

Study contacts

Alexis TOULLEC
Contact
clinical@biosency.com
02 21 65 70 01 ext. +33
Stéphane JOUNEAU, MD
principal investigator · CHRU PONTCHAILLOU Rennes

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion